VitriVax, a Boulder-based vaccine formulation technology company, has announced a two-year, $3.6 million grant from the Bill & Melinda Gates Foundation.
The award—its second from the foundation—will fund development of a polio vaccine formulation for possible inclusion in combination pediatric vaccines. To that end, VitriVax will leverage its proprietary technology to identify thermostable “virus-like particles” to enhance the immune response of future vaccines. In addition, the technology may facilitate the co-formulation of multiple—otherwise incompatible—antigens in a single injection.
“Funding support from the Bill & Melinda Gates Foundation allows us to continue our efforts to advance global accessibility to human vaccines,” said VitriVax CEO Romulo Colindres. “We are honored to be part of the global drive to protect children from polio infection and contribute to polio eradication efforts.”
(Photo credit: Getty Images/sanjeri)
